The biopharmaceutical landscape is evolving rapidly. While traditional monoclonal antibodies (mAbs) remain a cornerstone of the industry, the explosive growth in new modalities like peptides and oligonucleotides is pushing downstream processing to its limits.
To discuss how Bio-Works is meeting these challenges head-on, our CEO, Lone Carlbom, recently sat down with Oscar Bergman at Redeye TV for an in-depth interview on the company’s commercial execution, production capacity, and strategic roadmap.
If you missed the interview, you can watch the full conversation below. Here are the top three takeaways for our customers and partners.
When asked about Bio-Works' primary focus areas, Lone highlighted a clear strategic shift toward the fastest-growing markets in biopharma: peptides and oligonucleotides.
While Bio-Works recently launched a highly competitive new product for the massive mAbs market (affimAb edge), the unique properties of our WorkBeads™ resins are particularly well-suited for smaller, complex molecules.
"There is an incredible amount of research and development happening in this area," Lone explained. "Here we see that we have a major competitive advantage, as our type of product has proven to deliver much higher purity for our customers—which is incredibly important." By continuing our clear progress in both affinity chromatography and oligonucleotide purification, we are positioning Bio-Works as the go-to partner for these high-value, hard-to-purify targets.
In the biopharma industry, a superior resin means nothing if it cannot be delivered on time and at scale. Securing the supply chain is a top priority for Bio-Works.
During the interview, Lone revealed plans to aggressively scale up our production capabilities in our Uppsala facility. Currently operating with a capacity to support approximately 150 MSEK in sales, Bio-Works is initiating an expansion project to double that capacity to 300 MSEK by 2027.
Crucially, this expansion requires only a minor investment (under 4-5 MSEK) within our existing footprint. "We want to grow," Lone noted, "and then we must also ensure we have the capacity to take on that business... the worst thing that could happen is that we cannot deliver, because then we lose market share very, very quickly."
By eliminating bottlenecks and increasing capacity, we ensure that our customers can scale their campaigns from the lab bench to full GMP manufacturing without supply chain anxiety.
Chromatography resins are critical raw materials, and the sales cycle in the biopharmaceutical industry is notoriously long—often taking three to five years from early development to commercial manufacturing.
To bridge this gap and support customers globally, Bio-Works has spent the last two years hyper-focused on commercial execution. In addition to optimizing our internal sales organization, we have actively expanded our network of specialized distributors.
A prime example is the strategic partnership with Zenmindes Biotechnology Co., Ltd., signed this past autumn, aimed at establishing a strong and sustainable presence in China's rapidly expanding biopharmaceutical market. By partnering with distributors who deeply understand the complex purification needs of local markets, we are getting involved earlier in our customers' development phases.
As Bio-Works moves forward, the mission is clear: execute our commercial plans, double our production capacity, and secure the business for the future—all while maintaining strict cost control to reach our goal of breaking even by 2027.
With sustainable profitability within reach and a strengthened cash flow, Bio-Works is built on a stable foundation to support the next era of biopharmaceutical breakthroughs.